FDA Switch on Biologics Applauded
Agency Will Move Review For Biologic Drugs to More Experienced Division

BY MARION WEBB
Senior Staff Writer

The announcement by the Food and Drug Administration that reviews for many biological products will be moved from the agency's Center for Biologics Evaluation and Research to the Center for Drug Evaluation and Research took some biotechnology industry members by surprise...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129